Commonwealth Equity Services LLC Cuts Position in Pfenex Inc (NYSEAMERICAN:PFNX)

Commonwealth Equity Services LLC lessened its holdings in Pfenex Inc (NYSEAMERICAN:PFNX) by 6.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 79,065 shares of the biotechnology company’s stock after selling 5,200 shares during the period. Commonwealth Equity Services LLC owned about 0.25% of Pfenex worth $667,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also made changes to their positions in the stock. Janus Henderson Group PLC acquired a new stake in Pfenex in the 2nd quarter worth about $91,000. Meeder Asset Management Inc. boosted its holdings in Pfenex by 308.7% in the 2nd quarter. Meeder Asset Management Inc. now owns 8,755 shares of the biotechnology company’s stock worth $59,000 after buying an additional 6,613 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Pfenex by 72.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 84,018 shares of the biotechnology company’s stock worth $478,000 after buying an additional 35,418 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in Pfenex by 39.8% in the 2nd quarter. Acadian Asset Management LLC now owns 231,620 shares of the biotechnology company’s stock worth $1,561,000 after buying an additional 65,986 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Pfenex by 14.1% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 71,359 shares of the biotechnology company’s stock worth $481,000 after buying an additional 8,799 shares during the last quarter.

In other news, insider Patrick K. Lucy sold 6,000 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $8.00, for a total transaction of $48,000.00.

PFNX has been the topic of several research analyst reports. JMP Securities lifted their price objective on Pfenex from $13.00 to $17.00 and gave the stock an “outperform” rating in a report on Wednesday, September 11th. Cantor Fitzgerald began coverage on Pfenex in a report on Thursday, October 24th. They issued an “overweight” rating and a $20.00 price objective on the stock. Zacks Investment Research upgraded Pfenex from a “sell” rating to a “hold” rating in a report on Tuesday, November 12th. Finally, William Blair restated a “buy” rating on shares of Pfenex in a report on Friday, October 11th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $14.92.

Shares of Pfenex stock opened at $8.82 on Monday. Pfenex Inc has a 1-year low of $3.13 and a 1-year high of $11.39.

Pfenex (NYSEAMERICAN:PFNX) last issued its earnings results on Thursday, November 7th. The biotechnology company reported $0.09 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.09. The company had revenue of $15.25 million for the quarter, compared to analyst estimates of $14.80 million.

About Pfenex

Pfenex Inc, a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study.

See Also: How liquidity affects the bid-ask spread

Institutional Ownership by Quarter for Pfenex (NYSEAMERICAN:PFNX)

Receive News & Ratings for Pfenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex and related companies with MarketBeat.com's FREE daily email newsletter.